Recognizing obesity as a chronic disease can improve treatment, address complications, and reshape healthcare strategies for ...
Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with ...
Scientists mapped fat tissue differences in obese individuals, uncovering cell changes linked to metabolic disease risk and ...
Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within o ...
Is obesity a risk factor or a disease? This debate shapes treatments, policies, and eating disorder care. Explore its impact ...
The percentage of U.S. adults with obesity did not significantly rise from 2013 to 2023, though a small uptick in the rate of ...
A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.
A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!
Nita Ambani recently revealed about the obesity struggles that Anant Ambani deals. The conversation they had before his ...
Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.
The main results of the SUMMIT trial, reported last year, showed that tirzepatide—a dual glucose-dependent insulinotropic ...
Jan. 27, 2025 — A study shows that patients with obesity and fatty liver-related cirrhosis who had bariatric (weight-loss) surgery significantly lowered their future ... Signposting Children to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results